Evidence map›Paper›PMID 39888589›Full record

ReviewAmerican journal of clinical dermatology2025

Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.

Allison Yan, Lauren Madigan, Abraham Korman, Sabrina Shearer, Brittany Dulmage, Tejesh Patel, Nima Milani-Nejad, Catherine Chung, Kristopher Fisher, Benjamin Kaffenberger

Abstract readReview
In one paragraph

Review in American journal of clinical dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Allison YanThe Ohio State University College of Medicine, Columbus, OH, USA.
Lauren MadiganDepartment of Dermatology, The University of Utah, Salt Lake City, UT, USA.
Abraham KormanDepartment of Dermatology, The Ohio State University, 1328 Dublin Rd, Suite 100, Columbus, OH, 43212, USA.
Sabrina ShearerDepartment of Dermatology, Duke University, Durham, NC, USA.
Brittany DulmageDepartment of Dermatology, The Ohio State University, 1328 Dublin Rd, Suite 100, Columbus, OH, 43212, USA.
Tejesh PatelDepartment of Dermatology, The University of Tennessee, Memphis, TN, USA.
Nima Milani-NejadDepartment of Dermatology, University of California Los Angeles, Los Angeles, CA, USA.
Catherine ChungDepartment of Dermatology, The Ohio State University, 1328 Dublin Rd, Suite 100, Columbus, OH, 43212, USA.
Kristopher FisherDepartment of Dermatology, The Ohio State University, 1328 Dublin Rd, Suite 100, Columbus, OH, 43212, USA.
Benjamin KaffenbergerDepartment of Dermatology, The Ohio State University, 1328 Dublin Rd, Suite 100, Columbus, OH, 43212, USA. Benjamin.kaffenberger@osumc.edu.ORCID http://orcid.org/0000-0001-8079-0011

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Morbilliform eruptions, which are a clinical reaction pattern characterized by erythematous macules and papules coalescing into patches that cover most of the skin surface, are one of the most common cutaneous findings in the inpatient setting. In the hospital setting, most causes are benign and due to low-risk drug exanthems; however, morbilliform eruptions may also be a sign of high-risk diseases, including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, acute generalized exanthematous pustulosis, and graft-versus-host disease. Proper identification of the etiology and risk stratification of a morbilliform eruption is critical to ensure proper management and optimize patient outcomes. In this review, we discuss the key features that differentiate high-risk from low-risk morbilliform eruptions, as well as specific characteristics that differentiate the different high-risk eruptions. Additionally, we offer a clinical algorithm that may be applied in the management of a patient who presents with a morbilliform rash.

Indexed as

Drug EruptionsGraft vs Host DiseaseAcute Generalized Exanthematous PustulosisAlgorithmsDiagnosis, DifferentialDrug Hypersensitivity SyndromeHumansRisk AssessmentRisk FactorsSkinStevens-Johnson Syndrome

Identifiers

PMID39888589
PMCPMC12085335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.